U.S. Markets closed

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.04-0.03 (-0.15%)
At close: 4:00PM EDT
Sign in to post a message.
  • O
    Oscar
    Treatment AL001 showed slowed clinical progression by 47% this just published report is reason share price is crashing.
  • O
    Oscar
    What I said before the results are not good or not good enough so stock is down 21% !!
  • M
    Miller
    I am stepping back to look inside the data and also incorporate my perceptions from the call. I believe the results are very good. 47% is a very good number. I also think the Alector team presented that same perspective on the call. I thought I caught a little defensiveness from Alector mgt because they did feel their data results were compelling, but not many of the analysts seemed to agree wholeheartedly. I got the idea the small sample size and the lack of an actual control group may be impacting both 1)how enthused the analysts seem to be and 2)the today's reduction in sp. If they have a robust PH3 and hit the 47% number again, the results would be considered wildly successful. Disappointed for today though. Thought they had their act together this time. At least they have the GSK deal.
    That should be a good source of revenue for the next couple of years and also help with the expenses of PH3 clinical trials.
  • J
    Jeff
    It’s just a presentation of the study methodology and the biomarkers no conclusions or data included yet
  • M
    Miller
    Yes, people. The "Oscar interpretation" is either intentionally misleading or just remarkably misinformed. Very good results. Hold onto what you have! Listen to 1:00 call.
  • O
    Oscar
    We won’t see real results before 2023 so investment is a bit like dead money with a high risk that’s biotech. Afraid that we are soon back at the IPO price. Even the huge cash pile after the deal with GSK is no reason to lift up the share price. I am a long term investor and might consider to buy some more at lower levels. It’s important to spread your portfolio. Not only biotech.
  • M
    Miller
    SP will be depressed until Thursday, imho. May push lower and lower to generate anxiety among holders that just don’t want to lose what they have gained so far. That’s not why I am in. Been waiting for a year on Thursdays data release. NO WAY I am changing that focus. Hang in there longs! Gotta believe in the boost coming after embargo is lifted on Thursday.
    Bullish
  • M
    McManus
    it's all about the science folks. if results are good this stock is a coiled spring... it's dirt cheap next to avxl, dnli and sava. dnli is a quality outfit but avxl and sava are a bit shady. Alec is super high quality with a huge cash reserve, multiple shots on goal and two major pharma collaborations. we just need to see more out of the clinic.
  • O
    Oscar
    Denali Therapeutics is 15% down on mixed results and this is probably the reason that Alector is also down.
  • O
    Oscar
    If we continue this down trend soon back at IPO price USD 19. Doesn’t make sense with the GSK deal in the pocket.
  • O
    Oscar
    Almost back at IPO price USD 19 with the difference that we now have a huge cash pile thanks to GSK.
  • Y
    Yahoo Finance Insights
    Alector is down 15.44% to 25.79
  • M
    Miller
    A lot of shares sold today for a low price right before next week's Alz conference.
    Really puzzling....
  • M
    McManus
    possible that data leaked and not particularly bullish? seems very pronounced for a sympathy move
  • C
    Cole
    So I bought some when it was on its way up, will it keep going or are we thinking it dips?
  • M
    Miller
    Whew!...glad today is over. 🤔
  • P
    Paul
    It is a good company which focus on the R/D of anti- neurodegenerative disorders. This is very hot but very tough area with very high risks. The product pipeline shows the antibodies are on the clinical trials, which need towns of money. So the company must find collaborators to support it with money. The AL001 has got its phase 1 trial done, and phase II trial is on the way, Estimated Study Completion Date in May 30, 2023. And phase trial will end in December 30, 2023.
  • L
    Lee
    ALEC took a shot from the shorts and still finished green. There is a lot of strength to this run.
  • Z
    Zhang
    What happened? Why down today?
  • M
    Miller
    Looks like $40-$42 may be upper limit until more news comes our way. Nice run today :)
    Bullish